Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Replimune Group stock

REPL
US76029N1063
A2JQN1

Price

10.96
Today +/-
-0.18
Today %
-1.81 %
P

Replimune Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Replimune Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Replimune Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Replimune Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Replimune Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Replimune Group Stock Price History

DateReplimune Group Price
9/30/202410.96 undefined
9/27/202411.16 undefined
9/26/202411.13 undefined
9/25/202411.07 undefined
9/24/202411.07 undefined
9/23/202410.96 undefined
9/20/202410.91 undefined
9/19/202411.23 undefined
9/18/202411.08 undefined
9/17/202411.03 undefined
9/16/202410.46 undefined
9/13/202411.13 undefined
9/12/202410.38 undefined
9/11/202410.37 undefined
9/10/202410.34 undefined
9/9/202410.53 undefined
9/6/202410.37 undefined
9/5/202410.72 undefined
9/4/202410.44 undefined
9/3/202410.28 undefined

Replimune Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Replimune Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Replimune Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Replimune Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Replimune Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Replimune Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Replimune Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Replimune Group’s growth potential.

Replimune Group Revenue, EBIT and net profit per share

DateReplimune Group RevenueReplimune Group EBITReplimune Group Net Income
2030e397.82 M undefined494.9 M undefined111.5 M undefined
2029e311.57 M undefined-18.65 M undefined-5.57 M undefined
2028e218.45 M undefined-87.15 M undefined-36.24 M undefined
2027e122.57 M undefined-152.92 M undefined-137.46 M undefined
2026e16.64 M undefined-243.15 M undefined-193.47 M undefined
2025e2.72 M undefined-242.12 M undefined-216.54 M undefined
20240 undefined-234.77 M undefined-215.79 M undefined
20230 undefined-177.08 M undefined-174.28 M undefined
20220 undefined-118.31 M undefined-118.04 M undefined
20210 undefined-79.96 M undefined-80.87 M undefined
20200 undefined-56.2 M undefined-52.63 M undefined
20190 undefined-30.95 M undefined-30.83 M undefined
20180 undefined-19.23 M undefined-19.7 M undefined
20170 undefined-9.65 M undefined-7.7 M undefined

Replimune Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201720182019202020212022202320242025e2026e2027e2028e2029e2030e
00000000216122218311397
---------700.00662.5078.6942.6627.65
--------------
00000000000000
-9-19-30-56-79-118-177-234-242-243-152-87-18494
---------12,100.00-1,518.75-124.59-39.91-5.79124.43
-7-19-30-52-80-118-174-215-216-193-137-36-5111
-171.4357.8973.3353.8547.5047.4623.560.47-10.65-29.02-73.72-86.11-2,320.00
30.8430.8423.234.2646.2552.2158.2166.57000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Replimune Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Replimune Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20172018201920202021202220232024
               
20.661.6134.8168.6476.3395.7583.4420.67
00000000
00000000
00000000
0.40.83.72.74.55.36.38.08
2162.4138.5171.3480.8401589.7428.75
0.30.412.258.257.755.652.452.36
00000000
00000000
00000000
00000000
0.10.11.21.61.61.61.61.7
0.40.513.459.859.357.25454.06
21.462.9151.9231.1540.1458.2643.7482.8
               
31.686.400000.10.06
000.20.30.690.721.041.07
-9.2-28.9-59.8-112.3-193.2-311.2-485.5-701.28
-2.5-0.2-1.1-1-0.4-15.74.86
00000000
20.258.4137.7183.7498.6411.2555.3374.51
0.327.13.42.43.75.42.58
1.632.55.79.213.122.831.81
0.10.20.30.30.51.333.33
00000000
0002.42.52.62.62.72
25.29.911.814.620.733.840.44
006.634.824.724.452.668.22
00000000
0.71.703.75.14.84.94.56
0.71.76.638.529.829.257.572.78
2.76.916.550.344.449.991.3113.21
22.965.3154.2234543461.1646.6487.72
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Replimune Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Replimune Group's financial health and stability.

Assets

Replimune Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Replimune Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Replimune Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Replimune Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-7-19-30-52-80-118-174
0000122
0000000
01-1-153715
02914265056
0000001,000
0000000
-7-16-25-60-61-82-128
00-2-6-2-2-2
0-44-65-5-188-1-142
0-43,000-63,0001,000-186,0000-140,000
0000000
0009-10027
1554103903836283
15541011003726311
---2.00----
0000000
6-3934123-7640
-7.32-16.15-27.98-67.09-63.78-84.52-130.32
0000000

Replimune Group stock margins

The Replimune Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Replimune Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Replimune Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Replimune Group's sales revenue. A higher gross margin percentage indicates that the Replimune Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Replimune Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Replimune Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Replimune Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Replimune Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Replimune Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Replimune Group Margin History

Replimune Group Gross marginReplimune Group Profit marginReplimune Group EBIT marginReplimune Group Profit margin
2030e0 %124.4 %28.03 %
2029e0 %-5.99 %-1.79 %
2028e0 %-39.9 %-16.59 %
2027e0 %-124.76 %-112.15 %
2026e0 %-1,461.26 %-1,162.69 %
2025e0 %-8,901.58 %-7,961.11 %
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Replimune Group Stock Sales Revenue, EBIT, Earnings per Share

The Replimune Group earnings per share therefore indicates how much revenue Replimune Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Replimune Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Replimune Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Replimune Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Replimune Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Replimune Group Revenue, EBIT and net profit per share

DateReplimune Group Sales per ShareReplimune Group EBIT per shareReplimune Group Earnings per Share
2030e5.82 undefined0 undefined1.63 undefined
2029e4.56 undefined0 undefined-0.08 undefined
2028e3.2 undefined0 undefined-0.53 undefined
2027e1.79 undefined0 undefined-2.01 undefined
2026e0.24 undefined0 undefined-2.83 undefined
2025e0.04 undefined0 undefined-3.17 undefined
20240 undefined-3.53 undefined-3.24 undefined
20230 undefined-3.04 undefined-2.99 undefined
20220 undefined-2.27 undefined-2.26 undefined
20210 undefined-1.73 undefined-1.75 undefined
20200 undefined-1.64 undefined-1.54 undefined
20190 undefined-1.33 undefined-1.33 undefined
20180 undefined-0.62 undefined-0.64 undefined
20170 undefined-0.31 undefined-0.25 undefined

Replimune Group business model

Replimune Group Inc is an American biotechnology company based in Woburn, Massachusetts. The company focuses on the development of therapeutics for cancer treatments through the application of oncolytic viruses. Replimune Group is one of the most popular companies on Eulerpool.com.

Replimune Group SWOT Analysis

Strengths

Replimune Group Inc has several strengths that give it a competitive edge in the market. These include:

  • Strong research and development capabilities, allowing for innovative product development.
  • Patented technologies and intellectual property rights, protecting the company's innovations.
  • A team of highly skilled and experienced professionals dedicated to advancing the company's mission.
  • A solid financial position and access to funding, facilitating growth and expansion.
  • A strategic partnership network, providing access to resources, expertise, and potential collaborations.

Weaknesses

Despite its strengths, Replimune Group Inc also faces certain weaknesses that may hinder its growth and profitability. These weaknesses include:

  • Dependency on a limited number of product candidates, increasing the risk of failure in clinical trials.
  • Relatively small scale compared to some competitors, limiting market penetration.
  • Higher production costs due to the complex nature of its products.
  • Potential challenges in obtaining regulatory approvals for its therapies, leading to delays in commercialization.
  • Reliance on third-party suppliers for certain components, creating vulnerability to supply chain disruptions.

Opportunities

Replimune Group Inc can capitalize on several opportunities in the market to enhance its growth prospects. These opportunities include:

  • Increasing demand for advanced immunotherapies in the healthcare industry.
  • Expanding collaborations with research institutions and pharmaceutical companies to drive innovation.
  • Emerging markets with untapped potential, offering opportunities for geographical expansion.
  • The ability to leverage advancements in technology and data analytics to improve product development and patient outcomes.
  • Acquisitions or strategic partnerships to enhance the company's product portfolio and market presence.

Threats

Replimune Group Inc faces various threats that could impact its performance and market position. These threats include:

  • Intense competition from established pharmaceutical companies and emerging biotech firms.
  • Potential for regulatory changes or new regulations that could affect the approval process for therapies.
  • Uncertainty in healthcare policies and reimbursement systems, impacting market access and profitability.
  • Risks associated with clinical trials, including safety concerns, efficacy limitations, and unexpected results.
  • Shifts in market dynamics, such as changes in customer preferences or economic downturns, affecting demand for products.

Replimune Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Replimune Group historical P/E ratio, EBIT multiple, and P/S ratio

Replimune Group shares outstanding

The number of shares was Replimune Group in 2023 — This indicates how many shares 58.21 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Replimune Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Replimune Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Replimune Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Replimune Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Replimune Group.

Replimune Group latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.87 -0.78  (10.17 %)2025 Q1
3/31/2024-0.81 -0.82  (-1.43 %)2024 Q4
12/31/2023-0.95 -0.77  (18.62 %)2024 Q3
9/30/2023-0.87 -0.9  (-3.12 %)2024 Q2
6/30/2023-0.86 -0.75  (12.88 %)2024 Q1
3/31/2023-0.69 -0.74  (-7.68 %)2023 Q4
12/31/2022-0.77 -0.69  (10.33 %)2023 Q3
9/30/2022-0.8 -0.79  (0.98 %)2023 Q2
6/30/2022-0.66 -0.78  (-18.96 %)2023 Q1
3/31/2022-0.6 -0.6  (-0.67 %)2022 Q4
1
2
3

Eulerpool ESG Scorecard© for the Replimune Group stock

Eulerpool World ESG Rating (EESG©)

44/ 100

🌱 Environment

43

👫 Social

75

🏛️ Governance

14

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Replimune Group shareholders

%
Name
Stocks
Change
Date
9.58567 % T. Rowe Price Associates, Inc.6,548,930839,3823/31/2024
9.49458 % State Street Global Advisors (US)6,486,6961,375,1753/31/2024
7.12310 % Forbion Capital Partners4,866,4995012/31/2023
5.72095 % BlackRock Institutional Trust Company, N.A.3,908,556523,10412/31/2023
5.65758 % Redmile Group, LLC3,865,258-298,66412/31/2023
5.48520 % Morgan Stanley & Co. LLC3,747,4923,299,60212/31/2023
4.39303 % Omega Fund Management, LLC3,001,319012/31/2023
3.99510 % The Vanguard Group, Inc.2,729,453141,65412/31/2023
3.21419 % Goldman Sachs & Company, Inc.2,195,9381,684,17312/31/2023
3.07128 % Atlas Venture2,098,300012/31/2023
1
2
3
4
5
...
10

Replimune Group Executives and Management Board

Dr. Robert Coffin58
Replimune Group President, Director, Chief Research & Development Officer (since 2015)
Compensation 5.72 M
Mr. Philip Astley-Sparke52
Replimune Group Chief Executive Officer, Director (since 2015)
Compensation 3.65 M
Mr. Sushil Patel52
Replimune Group Chief Strategy Officer
Compensation 2.6 M
Dr. Colin Love65
Replimune Group Chief Operating Officer
Compensation 1.3 M
Dr. Pamela Esposito49
Replimune Group Chief Business Officer
Compensation 1.23 M
1
2
3
4

Most common questions regarding Replimune Group

What values and corporate philosophy does Replimune Group represent?

Replimune Group Inc represents values of innovation, integrity, and patient-centricity. With a strong corporate philosophy, they focus on developing oncolytic immunotherapies to combat cancer. The company is dedicated to advancing cutting-edge science and technology to provide effective and transformative treatments for patients. Replimune Group Inc strives to deliver innovative solutions that address unmet medical needs and improve the quality of life for cancer patients. Emphasizing collaboration, they work closely with industry partners and medical professionals to advance their research and impact the lives of millions affected by cancer.

In which countries and regions is Replimune Group primarily present?

Replimune Group Inc is primarily present in the United States.

What significant milestones has the company Replimune Group achieved?

Replimune Group Inc has achieved numerous significant milestones. The company successfully completed its initial public offering (IPO) in July 2018, raising funds to support its research and development activities. In September 2019, Replimune reported positive preliminary data from its Phase 1 clinical trials of RP1 in combination with nivolumab for advanced solid tumors. Later, in May 2020, the company announced positive overall survival data from the Phase 2 portion of the same trial. Replimune also received Fast Track designation from the U.S. FDA for RP1 in advanced cutaneous squamous cell carcinoma. These milestones demonstrate the company's progress, innovation, and potential for future growth.

What is the history and background of the company Replimune Group?

Replimune Group Inc is a pioneering biotechnology company focused on developing innovative cancer therapeutics. Founded in 2015, Replimune is dedicated to harnessing the power of oncolytic immunotherapies to treat a wide range of solid tumors. The company's novel approach involves engineering a specific virus to selectively replicate and destroy cancer cells while stimulating the immune response. Replimune's groundbreaking technology, known as Immulytic™, has shown promising results in early-stage clinical trials for various cancers. With a strong commitment to advancing patient care and improving outcomes, Replimune Group Inc is poised to make significant contributions to the field of cancer treatment.

Who are the main competitors of Replimune Group in the market?

The main competitors of Replimune Group Inc in the market are established pharmaceutical companies with a focus on developing oncolytic immunotherapies. These competitors include leading players in the biotechnology sector such as Amgen, Inc., Merck & Co., Inc., and Bristol Myers Squibb Company. Replimune Group Inc, a clinical-stage biotechnology company, aims to leverage its innovative immuno-oncology platform to develop next-generation cancer treatments. With its unique portfolio and cutting-edge technologies, Replimune Group Inc strives to distinguish itself among its industry counterparts and contribute to advancements in the field of oncolytic immunotherapies.

In which industries is Replimune Group primarily active?

Replimune Group Inc primarily operates in the biotechnology industry.

What is the business model of Replimune Group?

Replimune Group Inc operates under a business model focused on developing and commercializing oncolytic immunotherapies for the treatment of cancer. The company's innovative approach involves the use of its proprietary platform, called Immulytic™, which is designed to enhance the body's immune response against tumors. Replimune's therapies are aimed at both solid tumors and hematologic malignancies, with a focus on providing patients with a potentially transformative treatment option. By leveraging its deep understanding of immunology and expertise in viral-based therapeutics, Replimune Group Inc strives to make a significant impact in the fight against cancer.

What is the P/E ratio of Replimune Group 2024?

The Replimune Group P/E ratio is -3.38.

What is the P/S ratio of Replimune Group 2024?

The Replimune Group P/S ratio is 0.

What is the AlleAktien quality score of Replimune Group?

The AlleAktien quality score for Replimune Group is 2/10.

What is the revenue of Replimune Group 2024?

The revenue cannot currently be calculated for Replimune Group.

How high is the profit of Replimune Group 2024?

The Replimune Group profit is -215.79 M USD.

What is the business model of Replimune Group

Replimune Group Inc is a biopharmaceutical company specializing in the development of cell-based therapies for the treatment of cancer. The business model of Replimune Group is based on the development and commercialization of therapy products based on the technology of oncolytic viruses. This technology uses viruses that have been developed to infect and destroy tumor cells. Replimune Group has several products in its portfolio that are based on the fundamental technology of oncolytic viruses. These products are designed to enhance the body's immune response to tumor cells and directly destroy tumor cells. Replimune Group's products are targeted at a wide range of patients suffering from various types of cancer. Replimune Group operates its business activities in various divisions, including research and development, clinical trials, and marketing. The company has a strong research and development department that constantly develops new technologies and products to improve the quality and efficacy of its products. The company also conducts clinical trials to evaluate the efficacy of its products and ensure their safety. Through these studies, the company can also improve and optimize its products to provide better treatment for patients. The marketing of Replimune Group's products is done through the establishment of partnerships with other companies in the biotechnology and pharmaceutical sectors, as well as through direct marketing to hospitals and medical facilities. The company also has a sales department that focuses on marketing its products to oncologists, hematologists, and other specialists. Replimune Group has achieved a strong position in the field of oncolytic viruses in recent years and has become one of the leading companies in this field. According to estimates by the company, the market for oncolytic viruses is expected to grow exponentially in the coming years, providing Replimune Group with an excellent opportunity to further market and expand its products. Overall, the business model of Replimune Group Inc is focused on the development and marketing of products for the treatment of cancer based on the technology of oncolytic viruses. The company operates its business activities in various divisions, including research and development, clinical trials, and marketing. With this strategy, the company has achieved a strong position in the biotechnology and pharmaceutical sectors and has a promising future in oncology research and development.

What is the Replimune Group dividend?

Replimune Group pays a dividend of 0 USD distributed over payouts per year.

How often does Replimune Group pay dividends?

The dividend cannot currently be calculated for Replimune Group or the company does not pay out a dividend.

What is the Replimune Group ISIN?

The ISIN of Replimune Group is US76029N1063.

What is the Replimune Group WKN?

The WKN of Replimune Group is A2JQN1.

What is the Replimune Group ticker?

The ticker of Replimune Group is REPL.

How much dividend does Replimune Group pay?

Over the past 12 months, Replimune Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Replimune Group is expected to pay a dividend of 0 USD.

What is the dividend yield of Replimune Group?

The current dividend yield of Replimune Group is .

When does Replimune Group pay dividends?

Replimune Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Replimune Group?

Replimune Group paid dividends every year for the past 0 years.

What is the dividend of Replimune Group?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Replimune Group located?

Replimune Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Replimune Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Replimune Group from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Replimune Group pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Replimune Group in the year 2023?

In the year 2023, Replimune Group distributed 0 USD as dividends.

In which currency does Replimune Group pay out the dividend?

The dividends of Replimune Group are distributed in USD.

All fundamentals about Replimune Group

Our stock analysis for Replimune Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Replimune Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.